产品详情
所在位置: 首页> 产品目录> 一抗>
  • 产品名称:anti-APPantibody(Amyloidbeta(A4)PrecursorProtein)(pSer730)

  • 产品型号:
  • 产品厂商:Acris-antibodies
  • 产品文档:
你添加了1件商品 查看购物车
简单介绍:
anti-APPantibody(Amyloidbeta(A4)PrecursorProtein)(pSer730)
详情介绍:
Immunogen This antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S730 of human APP.
Isotype Ig
Specificity This antibody detects APP pSer730. Predicted to cross react with Mouse (100 % Antigen Homology).
Purification Protein G Affinity Chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with control and phosphorylated peptides. The phospho-specific antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name Amyloid beta A4 Protein / APP (APP Antibody Abstract)
Background APP is a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy).Synonyms: ABPP, APPI, Alzheimer disease amyloid protein, Amyloid Precursor Protein, CVAP, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II
Molecular Weight 86943 Da
Gene ID 351, 9606
UniProt P05067
Research Area Neurology, Alzheimer's Disease
Pathways Caspase Cascade in Apoptosis, EGFR Signaling Pathway, Transition Metal Ion Homeostasis, Skeletal Muscle Fiber Development, Toll-Like Receptors Cascades, Feeding Behaviour
Application Notes ELISA: 1/1,000. Western Blot: 1/100-1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer PBS with 0.09 % (W/V) Sodium Azide as preservative.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Supplier Images
 image for anti-APP antibody (Amyloid beta (A4) Precursor Protein) (pSer730) (ABIN358081) anti-Amyloid beta (A4) Precursor Protein (APP) (pSer730) antibody
Background publications Borroni, Colciaghi, Caltagirone, Rozzini, Broglio, Cattabeni, Di Luca, Padovani: "Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study." in: Archives of neurology, Vol. 60, Issue 12, pp. 1740-4, 2003 (PubMed).

Lleó, Berezovska, Ramdya, Fukumoto, Raju, Shah, Hyman: "Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression." in: The Journal of biological chemistry, Vol. 278, Issue 48, pp. 47370-5, 2003 (PubMed).

Zhou, Su, Li, Liu, Ryder, Wu, Gonzalez-DeWhitt, Gelfanova, Hale, May, Paul, Ni: "Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho." in: Science (New York, N.Y.), Vol. 302, Issue 5648, pp. 1215-7, 2003 (PubMed).

Murakami, Irie, Morimoto, Ohigashi, Shindo, Nagao, Shimizu, Shirasawa: "Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease." in: The Journal of biological chemistry, Vol. 278, Issue 46, pp. 46179-87, 2003 (PubMed).

Kim, Kim, Lee, Choi, Kim, Huh, Lee, Han, Rha: "Amyloid beta peptide (Abeta42) activates PLC-delta1 promoter through the NF-kappaB ." in: Biochemical and biophysical research communications, Vol. 310, Issue 3, pp. 904-9, 2003 (PubMed).